Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.

Source: MarketWatch | Published: March 18, 2025, 3:40 p.m.

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.

Read Original Article Back to News List

Related News

Morgan Stanley is the latest bank to trim its workforce. Here’s why.

2 hours, 27 minutes ago

Netflix paid $55 million for a show. Prosecutors say the creator blew it on Rolls Royces and crypto.

2 hours, 38 minutes ago

Google plans to buy cybersecurity company Wiz for $32 billion. Here’s why the startup is so valuable.

2 hours, 44 minutes ago

Nvidia’s stock falls after GTC. Here’s why Wall Street wasn’t so impressed.

2 hours, 51 minutes ago

Rescue of stranded astronauts is a win for Musk. This fund offers a ride on the SpaceX roller coaster.

2 hours, 52 minutes ago